• EU proposes measures targeting microplastic pollution
• Enhanced cost control
• Our model implies a fair valuation of SEK 10.5 per share

During the third quarter, Bioextrax reached a commercial milestone when the American licensee exercised its option to advance in the existing licensing agreement. The licensee will be able to produce up to 1,000 tons of PHA annually starting from October 2023. In summary, the Q3 figures led to minor changes in our model. We maintain our fair value of SEK 10.5 per share. Looking ahead, we continue to expect some of the current customer discussions to materialise into term sheets. We see this as crucial to support our valuation.

The initial research report is available here.